The company is in Phase 3 trials with atrasentan for IgA nephropathy (IgAN).
Revenue was flat year-over-year, and the company forecast a surprise decline in the current quarter.
No reason was given for the departure.
Target stock lost 25% of its value on Wednesday.
The VIX is akin to an insurance policy on the markets.